ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX · Real-Time Price · USD
1.630
+0.230 (16.43%)
At close: Nov 4, 2024, 4:00 PM
1.580
-0.050 (-3.07%)
Pre-market: Nov 5, 2024, 5:19 AM EST
ESSA Pharma Stock Forecast
EPIX's stock price has decreased by -72.83% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ESSA Pharma stock have an average target of 9.50, with a low estimate of 2.00 and a high estimate of 17. The average target predicts an increase of 482.82% from the current stock price of 1.63.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for ESSA Pharma stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $15 → $2 | Buy → Hold | Downgrades | $15 → $2 | +22.70% | Nov 4, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 4, 2024 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 1, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $17 | Buy | Maintains | $17 | +942.94% | May 16, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $17 | Buy | Reiterates | $17 | +942.94% | Dec 13, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.70
from -0.60
EPS Next Year
-0.93
from -0.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 23.4M | |||
| Avg | n/a | n/a | 5.7M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.63 | -0.65 | -0.70 | |||
| Avg | -0.70 | -0.93 | -1.38 | |||
| Low | -0.74 | -1.51 | -2.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.